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Objective: Diagnosing autoimmune encephalitis (AIE) is difficult in patients with less fulminant diseases such as epi-
lepsy. However, recognition is important, as patients require immunotherapy. This study aims to identify antibodies in
patients with focal epilepsy of unknown etiology, and to create a score to preselect patients requiring testing.
Methods: In this prospective, multicenter cohort study, adults with focal epilepsy of unknown etiology, without recog-
nized AIE, were included, between December 2014 and December 2017, and followed for 1 year. Serum, and if avail-
able cerebrospinal fluid, were analyzed using different laboratory techniques. The ACES score was created using
factors favoring an autoimmune etiology of seizures (AES), as determined by multivariate logistic regression. The model
was externally validated and evaluated using the Concordance (C) statistic.
Results: We included 582 patients, with median epilepsy duration of 8 years (interquartile range = 2–18). Twenty patients
(3.4%) had AES, of whom 3 had anti–leucine-rich glioma inactivated 1, 3 had anti–contactin-associated protein-like 2, 1
had anti–N-methyl-D-aspartate receptor, and 13 had anti–glutamic acid decarboxylase 65 (enzyme-linked immunosorbent
assay concentrations >10,000IU/ml). Risk factors for AES were temporal magnetic resonance imaging hyperintensities
(odds ratio [OR] = 255.3, 95% confidence interval [CI] = 19.6–3332.2, p < 0.0001), autoimmune diseases (OR = 13.31, 95%
CI = 3.1–56.6, p = 0.0005), behavioral changes (OR 12.3, 95% CI = 3.2–49.9, p = 0.0003), autonomic symptoms
(OR = 13.3, 95% CI = 3.1–56.6, p = 0.0005), cognitive symptoms (OR = 30.6, 95% CI = 2.4–382.7, p = 0.009), and speech
problems (OR = 9.6, 95% CI = 2.0–46.7, p = 0.005). The internally validated C statistic was 0.95, and 0.92 in the validation
cohort (n = 128). Assigning each factor 1 point, an antibodies contributing to focal epilepsy signs and symptoms (ACES)
score ≥ 2 had a sensitivity of 100% to detect AES, and a specificity of 84.9%.
Interpretation: Specific signs point toward AES in focal epilepsy of unknown etiology. The ACES score (cutoff ≥ 2) is
useful to select patients requiring antibody testing.
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Autoimmune encephalitis (AIE) associated with neuro-nal antibodies is a severe but treatable neurological
disease. Seizures occur frequently in patients with AIE
(50–95%), often in combination with other symptoms,
such as cognitive symptoms, behavioral changes, and auto-
nomic dysfunction.1–4 Seizures are often resistant to anti-
seizure medication (ASM), whereas the response to
immunotherapy is good.5,6 Most patients have fulminant
encephalitis with prominent seizures.
Neuronal antibodies have also been reported in
patients with epilepsy (14–31%).7–9 Results from these
studies have ensured that patients with less rapidly pro-
gressive encephalitis are being recognized as well. Never-
theless, in most of these studies, patients had short
epilepsy duration, and most of them had signs and symp-
toms of encephalitis. Interestingly, some of the mentioned
studies report patients with epilepsy without fulminant
encephalitis or even any sign of encephalitis. To compli-
cate interpretation, some of these studies describe a variety
of antibodies, some pathogenic, but others with question-
able clinical relevance.10,11
An important category comprises neuronal
antibody–positive epilepsy patients without other enceph-
alitis signs, because underdiagnosis is likely. It is essential
to recognize these patients early and to perform antibody
testing in preselected patients. At the same time, testing
needs to be rigorous, confirming results using different
tests, to avoid false positives or clinically irrelevant results.
Similarly, it is important to limit the number of patients
who require testing, for the sake of specificity and cost-
effectiveness.
The aim of our prospective, multicenter study was
to identify neuronal antibodies in a comprehensive cohort
of patients with focal epilepsy of unknown etiology, and
without, or with unrecognized, signs of encephalitis. We
have developed a clinical score, based on the prospectively
collected data of patients with focal epilepsy of unknown
etiology, that can be used to guide autoimmune etiology
of seizures (AES) screening. This antibodies contributing
to focal epilepsy signs and symptoms (ACES) score has
subsequently been validated in a second, external cohort.
Patients and Methods
Study Design, Participants, and Definitions
In this prospective, multicenter, observational cohort
study, adults with focal epilepsy of unknown etiology were
included by epileptologists between December 2014 and
December 2017. Patients included in this study had been
referred to (tertiary) epilepsy centers by neurologists who
had no particular suspicion of AIE. Patients were included
in the Netherlands, from tertiary epilepsy centers and
from dedicated epilepsy centers in academic hospitals, and
one general hospital with an epilepsy referral center. We
requested all epileptologists (1) to include patients with
epilepsy with or without additional symptoms, but with-
out suspicion of encephalitis; and (2) to exclude patients
strongly suspected of having AIE. Patients with epilepsy
with known infectious, genetic, or metabolic etiologies
were excluded. Patients with a structural lesion on brain
magnetic resonance imaging (MRI) at inclusion were
excluded, whereas patients with mesial temporal sclerosis,
or with T2/fluid-attenuated inversion recovery (FLAIR)
hyperintensities mainly in the mesial temporal lobe, both
unilateral and bilateral, were not, as these MRI findings
might be associated with AIE.12
International League against Epilepsy guidelines
were used to define focal seizures, an unknown etiology of
epilepsy, and drug-resistant epilepsy.13 The study was reg-
istered at ClinicalTrials.gov (NCT02802475).
Patients were classified as (1) definite AES if a
known neuronal antibody was detected in serum and/or
cerebrospinal fluid (CSF), and if results were confirmed
with a different laboratory test; (2) probable AES if a
known neuronal antibody was detected in serum and/or
CSF, but if we were unable to confirm the finding, or
when the diagnostic criteria for seronegative AIE were
met14; (3) possible AES, if serum or CSF showed similar
staining patterns on immunohistochemistry (IHC), but
without known antibody; and (4) non-AES.
Procedures
The including epileptologist or the coordinating investigator
(M.A.A.M.d.B.) completed a case record form at enroll-
ment, containing information about patient characteristics,
epilepsy characteristics, presence of autoimmune-associated
clinical signs or symptoms (disorders of memory, sleep,
behavior, speech, movement, or the autonomic system),
previous and current medication (including ASM), current
level of functioning (measured with modified Rankin Scale
[mRS]15), and results from prior ancillary testing (including
MRI, electroencephalogram [EEG], and if available CSF
analysis). Blood was drawn, and if CSF analysis was per-
formed, this was collected as well.
Patients were prospectively followed for 1 year (last
follow-up in December 2018). At 1, 4, 8, and 12 months
after inclusion, the treating physician or coordinating
investigator collected data about seizure type, monthly sei-
zure frequency, types of ASM used, and mRS. Final diag-
nosis was obtained at last follow-up.
Laboratory Methods
All samples were screened for immunoreactivity with
IHC, as previously described.16 Subsequently, all samples
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with a positive or questionable IHC result were tested
more extensively. A combination of laboratory techniques
was used, depending on the staining pattern and the clinical
phenotype. Commercial cell-based assay (CBA;
Euroimmun, Lübeck, Germany) was used to detect anti–
N-methyl-D-aspartate receptor (anti-NMDAR), anti–α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid recep-
tor (anti-AMPAR), anti–γ-aminobutyric acid B receptor
(anti-GABABR), anti–leucine-rich glioma-inactivated 1
(anti-LGI1), anti–contactin-associated protein- like 2 (anti-
CASPR2), and anti–glutamic acid decarboxylase 65 (anti-
GAD65). Anti-GAD65 was tested with enzyme-linked
immunosorbent assay (ELISA; Medizym anti-GAD 96,
Medipan, Berlin, Germany) as well, to quantify antibody
concentration. An in-house CBA with live cells was used to
detect anti-GABAAR, anti-GABABR, anti-AMPAR, and
anti–dipeptidyl-peptidase–like protein 6. Radioimmunoassay
(RIA; VGKC Antibody Assay RIA, DLD Diagnostika,
Hamburg, Germany) was used to detect voltage-gated
potassium channel complex antibodies (anti-VGKC), and
immunoblotting was used to detect onconeural antibodies
(anti-Hu/Yo/Ri/Tr/amphyphysin/CV2/Ma1/Ma2;
Euroimmun). We considered serum anti-GAD65 relevant
if the ELISA concentration was >10,000IU/ml. Only sam-
ples tested positive by ELISA and with a compatible posi-
tive staining on IHC were considered positive.17 In
addition, all serum samples were screened for the presence
of anti–glycine receptor (anti-GlyR) with an in-house CBA
with live cells, as these antibodies cannot be visualized with
IHC.18,19 All positive results were confirmed in separate
experiments.
Samples scored questionable or positive on IHC, but
without a known antibody, were tested more extensively
using immunocytochemistry with live hippocampal cell
cultures.16
A subgroup of patients considered for epilepsy sur-
gery were side by side tested by CBA, ELISA, and RIA for
antibodies, as a part of a standardized protocol. In addi-
tion, patients with an ACES score of 2 or more were
tested by commercial CBA and ELISA post hoc.
Statistical Analysis
Dutch Cohort
Patients were divided into 3 groups, based on antibody
test results: (1) antibodies targeting extracellular neuronal
antigens, (2) high-concentration anti-GAD65, and (3)
non-AES. Comparisons between the 3 groups (extracellu-
lar-AES, GAD-AES, and non-AES) were performed with
the Fisher–Freeman–Halton test, the Pearson Chi-square
test, or the Kruskal–Wallis test, when appropriate. To cor-
rect for multiple testing, we only considered p values
< 0.002 to be relevant (Bonferroni). Exploratory, post hoc
in-between analysis using the Fisher exact test and Mann–
Whitney U test was used to visualize group differences.
The patients with probable or possible AES were
not included in the analysis, and are only described on an
exploratory basis, as their etiology could not be confirmed
with certainty. We repeated analyses assigning these
patients to the non-AES group to assess the effects of
exclusion.
A multivariate logistic regression model was used to
identify independent risk factors pointing toward AES
(comparing both extracellular-AES and GAD-AES to non-
AES). Antibody status was used as dependent variable.
Missing values (0.8% of the total number of values) were
imputed. Multiple imputation was used to create 5 sample
sets, with antibody status included as covariate. We
excluded the factor “family history of autoimmune
diseases,” as we identified overt recall bias (lack of reliable
information in many patients without AES). The univari-
ate regression and multivariate regression models were
constructed using the imputed data. Variables with a
p value < 0.007 in univariate analysis (corrected for multi-
ple testing) were included in the multivariate logistic
regression model. To derive the ACES score, variables
were eliminated using a backward likelihood ratio method
with cutoff p value of 0.05. The selected risk factors were
used on the original and imputed data to check the accu-
racy. Each risk factor was assigned 1 point to create the
ACES score (range = 0–6 points). Sensitivity, specificity,
positive predictive value (PPV), and negative predictive
value (NPV) were calculated using the nonimputed
dataset. Percentages were visualized with 95% confidence
interval (CI) assuming a Poisson distribution.
The systematic difference in direction between the
Antibody Prevalence in Epilepsy and Encephalopathy
(APE), APE2 and ACES scores were compared using
McNemar paired test. Internal validation with boo-
tstrapping was used to estimate the degree of optimism in
the ACES score. In addition, Firth logistic regression was
used. We performed a sensitivity analysis to assess the
validity of our model allocating the excluded patients with
probable or possible AES to the non-AES group (to be
conservative).
Czech Cohort
External validation was performed in a Czech cohort con-
sisting of 128 temporal lobe epilepsy patients.20 In the
validation cohort, samples were tested by commercial
CBAs for anti-NMDAR, anti-AMPAR, anti-GABABR,
anti-CASPR2, and anti-LGI1 (Euroimmun) and immuno-
blot (PNS 11 Line Assay, Ravo Diagnostika, Freiburg,
Germany), confirmed by RIA for anti-GAD65 (CentAK
anti-GAD65 M, Medipan GMBH, Berlin, Germany). All
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positive and questionable samples had been tested by IHC
(F.L.). For uniformity, all questionable and positive sam-
ples were additionally tested by CBA, ELISA, and IHC in
Rotterdam (M.J.T.). All 6 risk factors used in the ACES
score had been collected prospectively in the Czech
cohort, and were retrieved from the database to calculate
the ACES score.
The model performance in this validation cohort
was described by discriminatory value, using the Concor-
dance (C) statistic (area under the curve of the receiver
operating curve) on the ACES model. Statistical analysis
was performed using SPSS Statistics 21 (IBM, Armonk,
NY), R statistical software version 3.6.2 (rms library), and
Prism 8.0.1 (GraphPad Software, San Diego, CA) for
Windows.
Ethics Committee Approval
The institutional review board of the Erasmus MC Uni-
versity Medical Center approved the study protocol
(MEC-2014-463). Written informed consent was
obtained from all patients.
Results
Patients: Dutch Cohort
Informed consent was obtained in 618 patients, of whom
36 (6%) were excluded (Fig 1). Of 582 included patients
with focal epilepsy of unknown etiology, 48% were male.
The median age at inclusion was 44 years (interquartile
range [IQR] = 29–58, range = 18–89). Ten percent of all
included patients had a history of autoimmune diseases.
Median epilepsy duration was 8 years (IQR = 2–18,
range = 0.1–75), whereas 66 patients (11%) had an epi-
lepsy duration of <1 year. Patients were treated with a
median of 1 ASM at inclusion (IQR = 1–2, range = 0–5).
MRI was normal in 532 patients (91%), whereas
T2/FLAIR hyperintensities of the mesial temporal lobe
were observed in 14 patients (2%), and 36 patients (6%)
had mesial temporal sclerosis. The EEG showed epileptic
discharges in 389 patients (67%). In 362 of these
389 patients, EEG reports were available. In 23%
(n = 83), seizures had a multifocal onset, whereas in 77%
(n = 279) there was a focal seizure onset, including tempo-
ral (39%, n = 108), frontotemporal (39%, n = 110), and
extratemporal (20%, n = 57) localization.
Results of Laboratory Studies
Serum was collected from all patients, and CSF was col-
lected from 46 patients (8%). In 20 of all 582 patients
(3.4%), neuronal antibodies related to AES were detected
(definite AES), including anti-LGI1 (n = 3), anti-CASPR2
(n = 3), anti-NMDAR (n = 1), and high-concentration
anti-GAD65 (n = 13). Of the 66 patients with epilepsy
for less than 1 year at inclusion, 6 had antibodies (9%; see
Fig 1).
Three patients of all 582 patients were scored as
probable autoimmune. One patient, with a neuropil
staining pattern on IHC, fulfilled the criteria of seronega-
tive AIE,14 whereas in serum of the other 2 patients anti-
GlyR were detected using CBA. Nine patients had a posi-
tive IHC, but no known antibody was identified, nor was
immunocytochemistry positive in any of these samples;
these patients were considered possible autoimmune.
Serum and CSF of 3 of these 9 patients showed a similar
“LGI1-like” staining pattern on IHC. In the other
6 patients, IHC showed a diffuse neuropil staining pat-
tern. No additional antibodies were detected in the
patients with questionable IHC staining patterns and neg-
ative live neurons (n = 36). In addition, 186 IHC negative
samples were tested by commercial antibody testing, partly
in parallel, and often as part of screening for epilepsy sur-
gery (n = 104). The other samples were tested because of
high ACES scores (ACES ≥2, n = 82; post hoc testing).
No antibodies were found in these samples.
Comparison between AES and Non-AES
Comparison of patients with antibodies against extracellu-
lar antigens (LGI1, CASPR2, NMDAR; n = 7), patients
with anti-GAD65 (n = 13), and non-AES patients
(n = 550; Table S1), showed that patients with AES (anti-
bodies against both extracellular antigens and GAD65)
more frequently had drug-resistant epilepsy (p = 0.002)
and uni- or bilateral T2/FLAIR hyperintensities of the
mesial temporal lobe (p < 0.0001), had higher mRS at
inclusion (p < 0.0001), and more often had cognitive
symptoms (p < 0.0001) and behavioral changes
(p < 0.0001; Fig 2). Post hoc in-between analysis showed
that patients with antibodies against extracellular antigens
were older at disease onset, were more frequently male,
had shorter epilepsy durations, and more frequently had
autonomic symptoms than patients with anti-GAD65 or
non-AES patients. Patients with high-concentration anti-
GAD65 were all female and more often had other autoim-
mune diseases, speech problems (word finding difficulties,
non-fluent speech), and muscle stiffness than patients with
antibodies against extracellular antigens or non-AES
patients.
ACES Score
Eight variables showed a statistically significant associa-
tion with antibody status in univariate analysis: drug-
resistant epilepsy, autoimmune diseases, behavioral
changes, cognitive symptoms, muscle stiffness, speech
problems, autonomic symptoms, and MRI hyper-
intensities of the mesial temporal lobe (Table 1 and
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Fig 2). The multivariate model included the following
factors: autoimmune diseases, behavioral changes, cogni-
tive symptoms, speech problems, autonomic symptoms,
and MRI hyperintensities of the mesial temporal lobe
(see Table 1). The internally validated C statistic was
0.95. To correct for optimism, penalized modeling was
performed showing similar odds ratios for all factors; all
remained significant and independent risk factors (data
not shown).
The external validation cohort consisted of 128 tem-
poral lobe epilepsy patients, of whom 7 had neuronal anti-
bodies (5.5%, compared to 3.4% in the Dutch cohort,
p = 0.30). Data of the Dutch and Czech cohort are
compared in Table S2, and results of the Czech
FIGURE 1: Flowchart with follow-up diagnosis of all included patients. *This patient had focal onset epilepsy with sporadically
occurring focal to bilateral tonic–clonic seizures, and had a recently discovered esophagus carcinoma. Eleven months after
inclusion, his seizure frequency increased, and he developed psychotic symptoms. Cerebrospinal fluid was positive for anti–N-
methyl-D-aspartate receptor (NMDAR), confirmed with live hippocampal neurons. #According to the criteria.14 AES =
autoimmune etiology of seizures; CASPR2 = contactin-associated protein-like 2; GAD65 = glutamic acid decarboxylase 65; GlyR
= glycine receptor; LGI1 = leucine-rich glioma-inactivated 1; MRI = magnetic resonance imaging.
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FIGURE 2: Overview of the characteristics, signs, and symptoms that occurred more often in patients with neuronal antibodies.
*p between 0.05 and 0.005, **p between 0.005 and 0.0001, ***p < 0.0001. The top p values correspond to the values visualized
in Table S1. The lighter-colored lines visualize significance of the post hoc in-between analysis. (A) Factors that differed
significantly between autoimmune etiology (AE) of seizures and non-AE. (B) Values that differed between the extracellular
antigen group and the non-AE group. (C) Values that differed between the GAD65 and non-AE groups. In order of appearance,
the y-axis shows: (1) years (age at onset), (2) cumulative percentage (all bar diagrams), (3) months and years (0–12, 1–80
respectively; epilepsy duration). In the bar diagrams, the x-axis shows the raw values. CASPR2 = contactin-associated protein-like
2; GAD65 = glutamic acid decarboxylase 65; LGI1 = leucine-rich glioma-inactivated 1; MRI = magnetic resonance imaging; mRS =
modified Rankin Scale; NMDAR = N-methyl-D-aspartate receptor. [Color figure can be viewed at www.annalsofneurology.org]
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antibody-positive patients are shown in Table S3. The
C statistic of our model for the external validation cohort
was 0.92, showing that the (overall) discriminative perfor-
mance is similar in the validation cohort.
The 6 independent risk factors were used to create
the ACES score, each factor assigning 1 point. Evaluating
different cutoff values for the ACES score (Fig 3) in the
original cohort, 19.4% (95% CI = 11.4–29.6) of the
patients with a score ≥ 2 had antibodies (PPV), whereas
none of the patients with < 2 risk factors had antibodies,
resulting in an NPV of 100% (95% CI = 81.4–100). Sen-
sitivity of an ACES score of ≥ 2 was 100% (95%
CI = 81.4–100), and specificity was 84.9% (95%
CI = 67.9–100; Table 2). No patient with an ACES scor-
e ≥ 2, but without AES (n = 83), was identified by com-
mercial tests, outside the planned screening algorithm (see
Fig 3B). In addition, we reviewed data of 55 Dutch anti-
NMDAR, 43 anti-LGI1, 19 anti-GAD65, and 14 anti-
CASPR2 patients with seizures. All of them, except
1 patient with anti-LGI1 (ACES score = 1), had an ACES
score of 2 or more. Using the same cutoff for the ACES
score, 37 patients in the Czech validation cohort had an
ACES score ≥ 2 (29%). All patients with AES were identi-
fied (see Fig 3C).20
Results from the sensitivity analysis (allocating the
12 patients with probable or possible AES [3 and
TABLE 2. Testing Properties of the ACES Score Using Different Cutoff Values
Cutoffa n (%)b PPV (95% CI) NPV (95% CI) Sensitivity (95% CI) Specificity (95% CI)
≥1 point 305 (53%) 6.5 (2.8–13.1) 100 (81.4–100) 100 (81.4–100) 48.2 (36.5–63.6)
≥2 point 103 (18%) 19.4 (12.2–29.7) 100 (81.4–100) 100 (81.4–100) 84.9 (67.9–100)
≥3 point 22 (4%) 54.5 (41.4–70.5) 98.5 (80.5–100) 60 (45.8–77.2) 98.2 (80.5–100)
≥4 point 1 (0.2%) 100 (81.4–100) 96.7 (78.7–100) 5 (1.6–11.7) 100 (81.4–100)
aThe six factors include: autoimmune diseases, behavioral changes, cognitive symptoms, speech problems, autonomic symptoms, temporal magnetic
resonance imaging hyperintensities.
bN = 570.
CI = confidence interval; NPV = negative predictive value; PPV = positive predictive value.
TABLE 1. Results from Univariate and Multivariate Analysis
Univariate Analysis Multivariate Analysis
Odds Ratio (95% CI)a pa Adjusted Odds Ratio (95% CI)a pa
Drug-resistant epilepsy 7.1 (2.1–24.5) 0.002 — —
Autoimmune diseases 8.2 (3.2–20.7) <0.0001 13.3 (3.1–56.6) 0.0005
Behavioral changes 11.0 (4.1–29.3) <0.0001 12.6 (3.2–49.9) 0.0003
Cognitive symptoms 31.8 (4.4–229.9) 0.001 30.6 (2.4–382.7) 0.009
Muscle stiffness 7.3 (1.9–28.7) 0.004 — —
Speech problems 12.8 (4.1–40.0) <0.0001 9.6 (2.0–46.7) 0.005
Autonomic symptoms 22.1 (6.4–75.5) <0.0001 23.3 (3.8–143.3) 0.001
Temporal MRI hyperintensities 16.9 (4.6–62.1) <0.0001 255.3 (19.6–3,332.2) <0.0001
The table only shows the data of patients with autoimmune etiology of seizures (n = 20), and with no evidence for autoimmunity (n = 550).
aNumbers shown are from the cohort data after imputation.
CI = confidence interval; MRI = magnetic resonance imaging.
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9 patients, respectively] to the non-AES group) showed
comparable odds ratios (a sensitivity of 100% and specific-
ity of 84.7%).
Comparing the ACES score (of both cohorts) to
the prior published APE/APE2 score,8,21 showed that
the APE/APE2 score detected 8 of 10 patients with anti-
bodies against extracellular proteins, and 7 of 17 patients
with anti-GAD65. All scores performed well in patients
with a short history of epilepsy, but the ACES score
scored better in patients with chronic epilepsy
(p = 0.0015; Fig 4).
Clinical Characteristics of the Dutch Cohort
Looking very carefully, additional subtle signs or symp-
toms of encephalitis/encephalopathy were present at inclu-
sion in 19 of 20 patients with AES. All patients with anti-
LGI1 had subtle characteristic signs, including cognitive
symptoms, insomnia, hyponatremia, and behavioral
changes, and 2 of 3 patients had faciobrachial dystonic sei-
zures (FBDS).22 Two of 3 patients with anti-CASPR2 had
other core signs or symptoms,23 albeit mild, including
cognitive symptoms, peripheral nerve hyperexcitability,
insomnia, autonomic symptoms, and cerebellar symptoms,
and 1 patient developed neuropathic pain after inclusion.
In both the anti-LGI1 and anti-CASPR2 patients, some
signs were identified in retrospect (insomnia, FBDS,
peripheral nerve hyperexcitability, cerebellar symptoms),
whereas others were observed but remained unrecognized
as AES-related (because of their subtleness, and concomi-
tant start of ASM). During follow-up, 1 patient with focal
epilepsy with sporadically occurring tonic–clonic seizures
and recently diagnosed esophagus carcinoma developed
hallucinations, refractory epilepsy, and psychosis. Anti-
NMDAR was detected in his CSF 11 months after inclu-
sion, whereas his serum was negative at baseline, but also
at 11 months after inclusion.
All 13 women with anti-GAD65 had a serum con-
centration > 10,000 IU/ml (median serum concentration =
466,000 IU/ml, median CSF concentration = 4,600IU/ml).
Five anti-GAD65 patients had diabetes mellitus type 1
(38%). All patients had focal onset seizures, most frequently
with sensory onset (déjà vu episodes; 9/13). Interestingly, in
4 patients, temporal seizures were clearly provoked by
music. Oligoclonal bands unique to the CSF were tested in
8 patients, of whom 5 tested positive.
In the “probable autoimmune” group, 1 patient
developed frequent seizures. Shortly afterward, he suffered
from abdominal symptoms and weight loss, which turned
out to be Crohn’s disease. He then continued to deterio-
rate, with progressive cognitive symptoms. He was treated
with steroids and adalimumab, leading to (slow) cognitive
improvement and cessation of seizures. He met the “sero-
negative AIE” criteria.14 The 2 patients with anti-GlyR
were a middle-aged male with drug-resistant epilepsy and
a young woman with sporadic seizures without other
signs.
In the “possible autoimmune” group, all 3 women
with a similar “LGI1-like” pattern on IHC had daily
drug-resistant focal onset seizures. In 2 of these 3 women,
ASMs were withdrawn because of ineffectiveness. The 9
patients with neuropil staining on IHC had variable
FIGURE 3: Autoimmune etiology of seizures (AES) patients as
distributed by ACES score. The number of AES patients by
ACES score (A) are provided for both the original, Dutch
cohort (B) and the Czech validation cohort (C). Only the data
of the patients with antibodies targeting extracellular
antigens, anti–glutamic acid decarboxylase 65 (GAD65), and
no evidence for autoimmunity are shown. The numbers in
the bar diagrams correspond with the numbers of patients of
each specific group. All patients with an ACES score of ≥2
without AES were tested by commercial cell-based assay and
enzyme-linked immunosorbent assay post hoc, and all were
negative. MRI = magnetic resonance imaging. [Color figure
can be viewed at www.annalsofneurology.org]
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clinical phenotypes. All clinical characteristics of the
patients with definite, probable, and possible AES are
shown in Tables S4 and S5.
In 550 patients, there was no evidence for autoim-
munity at last follow-up. Of these 550 patients, 96% were
diagnosed as focal epilepsy with unknown etiology,
whereas in the other patients ancillary testing led to
another diagnosis, including a symptomatic lesion on
revised or new MRI (n = 13), generalized epilepsy (n = 3),
dementia and seizures (n = 2), and no epilepsy (n = 2).
Immunotherapy Responses
All 6 patients with anti-LGI1 and anti-CASPR2 encepha-
litis were treated with immunotherapy (Fig 5A, B) and
became seizure-free (1 anti-LGI1 encephalitis patient
became seizure-free at 13 months, just outside the study
period), as did the anti-NMDAR encephalitis patient. Ten
of the 13 anti-GAD65 patients were treated with immu-
notherapy; 5 of them had a remarkable decrease in their
seizure frequency (see Fig 5C; 50–95%), deviating from
their seizure frequency the year before, whereas in the
other 5 patients no seizure frequency reduction was
observed (see Fig 5D). Three patients refused immuno-
therapy (reasons: less severe disease [n = 2] or fear of side
effects [n = 1]).
Discussion
In this prospective, multicenter cohort study, we show
that a small, but relevant, proportion of patients with focal
epilepsy of presumed unknown etiology have neuronal
FIGURE 4: Comparison of the ACES score with the Antibody Prevalence in Epilepsy and Encephalopathy (APE) and APE2 score.
(A) Visualization of the epilepsy scores per patient, combining the Dutch and Czech cohorts, shows that all patients are identified
by the ACES score, whereas a considerable percentage is not identified by the APE or APE2 score. (B) Dissection by duration of
epilepsy shows that the difference in performance is caused by the patients with epilepsy for >1 year. * p < 0.05, **p < 0.01.
The colors refer to the antibodies identified: red, contactin-associated protein-like 2; orange, leucine-rich glioma-inactivated 1;
green, N-methyl-D-aspartate receptor; blue, glutamic acid decarboxylase 65.
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antibodies. All patients with AES had unrecognized signs
of encephalitis. Identifying these patients is crucial,
because seizures respond better to immunotherapy than to
ASM, which is reflected by seizure freedom in all patients
with antibodies against extracellular proteins after immu-
notherapy. For recognition of AES patients, we have pro-
vided and validated a simple clinical score that helps
physicians in selecting patients who should be screened
for neuronal antibodies.
In the current study, neuronal antibodies were found
in 3.4% of patients, whereas other studies describe higher
numbers of >10%.7,8 The most important issue explaining
this discrepancy is the difference in patient selection. The
patients included in our study were referred to epilepsy
centers by neurologists who had no suspicion of AIE. In
retrospect, most of the patients with AES had subtle signs
or symptoms of AIE, but these signs were unrecognized as
being related to AIE. For example, insomnia, muscle stiff-
ness, or mild cognitive problems were often considered to
be side effects of ASM. In addition, patients were only
included in the AES group when substantial evidence for
autoimmunity for the detected antibodies was available. In
a smaller prospective cohort of patients with temporal lobe
epilepsy, the same antibodies were identified as in the
ACES study,20 whereas others found a greater variability
of antibodies.7,8 Some of the described antibodies are
pathogenic, like anti-NMDAR, and anti-GABABR, but
occurred in highly selected patients with clear encephalitis.
However, experiments to confirm antibody results were
lacking in some studies, although it is an essential neces-
sity when screening large cohorts, to avoid false positive
results. Prior studies also describe antibodies with a debat-
able role in neuroinflammation, including low-
concentration anti-GAD65, and double negative anti-
VGKC, nowadays considered clinically irrelevant by
most.10,11
The Czech study20 was used to externally validate
the results. This study was chosen because it was of a
FIGURE 5: Individual treatment responses of patients with anti–leucine-rich glioma-inactivated 1 (LGI1), anti–contactin-associated
protein-like 2 (CASPR2), and anti–glutamic acid decarboxylase 65 (GAD65). The figures visualize the seizure frequency over time
per antibody: (A) anti-LGI1, (B) anti-CASPR2, (C) anti-GAD65 with treatment response, (D) anti-GAD65 without treatment
response (both black), or untreated (gray). The Roman numerals correspond to the numbers shown in Table S4. All patients were
treated with antiseizure medications (ASM). The figure only shows ASM changes that led to a decrease in seizure frequency.
AED = antiepileptic drug; IVIg = intravenous immunoglobulin; −T12 = 12 months before inclusion, T0 = inclusion date,
T1 = 1 month after inclusion, T4 = 4 months after inclusion, T8 = 8 months after inclusion, T12 = 12 months after inclusion. [Color
figure can be viewed at www.annalsofneurology.org]
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considerable size, investigated chronic epilepsy as well
(median duration even longer), and did not included
patients referred for overt encephalitis. In contrast to our
study, all patients had temporal epilepsy, and they more
often had mesiotemporal sclerosis. Otherwise, the epide-
miological and clinical characteristics were largely similar.
Reassuringly, the antibody frequency and type of anti-
bodies (anti-LGI1, anti-CASPR2, anti-GAD65) were
within the same range.
We found anti-LGI1, anti-CASPR2, and anti-
GAD65. This is a comprehensible observation, because
the clinical phenotypes of patients with these syndromes
can be more prolonged and less aggressive, and diagnosis
is more likely to be delayed or missed than in patients
with clear encephalitis.1,12,22 Although clinical phenotypes
related to these antibodies can be less serious, immuno-
therapy is superior to ASM,5,17 which makes diagnosis in
an early phase important. Thirteen women had high anti-
GAD65 concentrations. Earlier performed laboratory
studies were unable to reveal the pathogenicity of anti-
GAD65.23 However, patients with high concentrations
have overlapping and well-defined neurological syn-
dromes, and comparable seizure characteristics, not
observed in low-concentration patients.17 Almost 75% of
the high-concentration anti-GAD65 women had déjà vu
episodes. In addition, one-quarter had musicogenic epi-
lepsy, meaning temporal seizures clearly triggered by spe-
cific music or songs, whereas the prevalence of
musicogenic epilepsy in other non-AES patients is very
low. Musicogenic epilepsy has been described before in
anti-GAD65 encephalopathy.24 Concerning immunother-
apy responses, in contrast to the patients with anti-LGI1
or anti-CASPR2, no patient became seizure-free. How-
ever, in one-half of the treated patients, a long-term epi-
lepsy frequency reduction of up to 95% was observed,
although these patients had been refractory to ASMs for a
significant time. This makes regression to the mean or
natural history as the explanation for the epilepsy fre-
quency reduction highly unlikely. In support, seizure
response was accompanied by a serological response.
The finding that only anti-LGI1, anti-CASPR2, and
anti-GAD65 occurred suggests that screening for these
antibodies only is generally sufficient in patients with focal
epilepsy of unknown etiology without clear encephalitis. If
anti-LGI1 is detected in serum and the phenotype fits,
diagnosis can be made, and treatment can be started.12 If
serum is positive for anti-CASPR2, CSF should be tested
as well.22 If the anti-GAD65 ELISA concentration is
>10,000IU/mL, this can be considered clinically rele-
vant.17 This is roughly comparable to an RIA titer of
20nmol/L8 or 2,000U/mL.24 In case of deterioration of
symptoms or suggestive signs or symptoms, antibody
testing should be expanded, taking into account the clini-
cal phenotype.
We identified 6 independent risk factors pointing
toward AES. The assessed risk factors were predefined
before the study started. The ACES score was created
assigning all factors 1 point instead of creating a value-
weighted score. The easier the score, the more likely it is
to be used in clinical settings. In addition, as our score is
meant to identify those who need antibody testing, our
primary aim was to create a sensitive score. Although a
weighted score would provide better model performance,
it would not increase the sensitivity (already optimal if at
least 2 factors of the ACES score were present). Lastly,
some of the odds ratios showed large confidence intervals
due to the low frequency in the control group of the origi-
nal cohort. By not assigning a weighted value, we lower
the risk of overfitting. Using a cutoff value of 2 for the
ACES score, all antibody-positive patients were identified,
but antibody testing was unrevealing in 14%. It should
therefore not be used to diagnose AES, but to guide selec-
tion of patients for antibody screening.
The factors included in the ACES score partially
overlap with those used in the APE/APE2 score.8,21 Nev-
ertheless, there are important differences, which makes
sense as, judging by the published papers of Dubey et al,
the scores serve different populations. Our study included
patients with focal epilepsy, all without overt encephalitis.
In addition, our ACES score was validated in another
chronic epilepsy cohort, and showed very good discrimina-
tion. In this study, we confirm that the APE/APE2 score
is useful to detect patients in a (sub)acute setting with
antibodies against extracellular neuronal antigens. How-
ever, almost 70% of chronic patients would have been
missed using this score, underlining the importance of a
score that is applicable to patients with variable disease
courses.
Some patients were classified as “probable or possi-
ble autoimmune.” Data for these patients were not used
in the main analysis, but inclusion would not have chan-
ged the results. Two patients categorized as “probable
autoimmune” had anti-GlyR. Clinical characteristics of
these 2 patients showed no notable similarities. Testing
serum of these patients consistently showed a positive
result on live CBA, but we were unable to analyze CSF or
to confirm our findings with additional techniques. Except
for these 2 epilepsy samples, we have not identified any
positive sample in 1,206 patients outside published clini-
cal phenotypes.19,25 Although anti-GlyR can be directly
pathogenic,18 we prefer to be careful in describing
unconfirmed findings. The “possible autoimmune” cate-
gory contained 3 patients with similar clinical characteris-
tics and drug-resistant epilepsy. Both serum and CSF
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showed an unknown pattern on IHC. We are currently
analyzing these samples using immunoprecipitation and
mass spectrometry. In 6 other patients, IHC showed a dif-
fuse neuropil staining However, live hippocampal neuron
staining was negative, CSF was not available for confirma-
tion, and patients had different clinical phenotypes, all
questioning the clinical relevance.
Our study has limitations. Due to the small number
of antibody-positive patients, there is a risk of overfitting.
Therefore, we also assessed a penalized model. In addition,
external validation in a second, independent, foreign
cohort showed comparable test characteristics. Concerning
data extraction, this was performed thoroughly; however,
it is possible that recall bias occurred, especially in the var-
iables that are not discussed in the standard intake. An
example is “family history of autoimmune diseases.” We
therefore decided to exclude this variable from the analy-
sis. Another limitation was the use of only serum in most
patients. Although highly sensitive to test for anti-LGI1,12
anti-CASPR2,22 anti-GAD65, and anti-GABABR,
26 it is
somewhat less sensitive to screen for anti-NMDAR27 or
anti-AMPAR.28 Testing only serum poses the risk of miss-
ing a small proportion of patients. However, both anti-
NMDAR and anti-AMPAR encephalitis tend to present
more fulminantly,2 and the syndromes would probably
have revealed themselves during follow-up, as exemplified
by the only patient who was antibody negative (in serum)
at inclusion, but who developed a panencephalitis
11 months after inclusion with anti-NMDAR in CSF. In
retrospect, it is unclear, because of the lack of CSF at
inclusion, whether this patient had anti-NMDAR, causing
his seizures before deterioration, or if he coincidentally
developed anti-NMDAR encephalitis later on. The pres-
ence of esophageal carcinoma in this case underlines the
importance of screening for tumors in these patients.29
Samples were screened with immunohistochemistry, and
questionable and positive samples were tested more thor-
oughly (CBAs, ELISA, live hippocampal neurons). This
approach was chosen because of the high sensitivity of
IHC.12,17,22,26–28,30,31 Although we cannot guarantee that
we have identified all patients, previous publications sup-
port our claim that this approach seems most reliable and
sensitive to test large cohorts of patients with low prior
chances, as also enforced by testing 186 samples negative
by IHC with additional CBA and ELISA without reveal-
ing additional antibodies.
To conclude, patients with AES present differently
and have specific, although not always discriminative charac-
teristics. Recognition of these patients can be difficult, but is
important for treatment decisions. An ACES score ≥ 2 can
be used to identify patients with higher risk of having AES,
and to select those who require antibody testing.
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